Last reviewed · How we verify
Intranasal dexmedetomidine-esketamine
This combination drug acts as an alpha-2 adrenergic agonist (dexmedetomidine) and an NMDA receptor antagonist (esketamine) delivered intranasally to produce rapid sedation and analgesia.
This combination drug acts as an alpha-2 adrenergic agonist (dexmedetomidine) and an NMDA receptor antagonist (esketamine) delivered intranasally to produce rapid sedation and analgesia. Used for Procedural sedation and analgesia, Acute pain management.
At a glance
| Generic name | Intranasal dexmedetomidine-esketamine |
|---|---|
| Sponsor | Peking University First Hospital |
| Drug class | Alpha-2 adrenergic agonist / NMDA receptor antagonist combination |
| Target | Alpha-2 adrenergic receptors; NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Sedation / Acute Pain Management |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine selectively binds alpha-2 adrenergic receptors in the central nervous system to produce sedation, analgesia, and anxiolysis. Esketamine is an NMDA receptor antagonist that provides rapid-onset dissociative anesthesia and analgesia. The intranasal formulation allows non-invasive delivery with faster onset than oral routes.
Approved indications
- Procedural sedation and analgesia
- Acute pain management
Common side effects
- Sedation
- Dizziness
- Dissociation
- Hypertension
- Tachycardia
Key clinical trials
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder (NA)
- Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia (PHASE4)
- S-ketamin Premedication in Pediatric EENT Surgery (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: